Secondary hyperparathyroidism can develop as a result of bone metastases from prostatic cancer, but this has not been studied from the multiple aspects of biochemistry, hormonal status and histomorphometry. In 20 patients with stage-D prostatic cancer, a transiliac bone biopsy was performed for histomorphometric study. In all of them, molecular parathormone (PTH-M) and osteocalcin were determined by radioimmunoassay together with other parameters considered to be biological markers of bone remodelling. Of these 20 patients, only 2 (10%) had elevated PTH-M (240 ± 20.6 pmol/l), differing significantly from the other 18 (58.6 ± 11.7 pmol/l) and from controls (60.4 ± 7.2 pmol/l). In the high PTH-M patients, corrected calcium was low (7.8 ± 0.4 mg/dl) as compared to normal PTH-M patients (9.2 ± 0.5 mg/dl, p < 0.001), and this was also the case for serum phosphorus (2.2 ± 0.6 vs. 3.2 ± 0.3 and 3.4 ± 0.4 mg/dl, respectively p < 0.001). Alkaline phosphatase was raised in the patient groups as compared to controls (p < 0.001) and was higher in the high PTH-M group (362 ± 58 vs. 224 ± 62 U/l, p < 0.001). The same pattem of higher values in the hyperparathyroid patients was repeated for: hydroxyproline/Cr in fasting urine (3.6 ± 0.2 vs. 2.1 ± 0.4 mg/mg, p < 0.001); Ca/Cr in fasting urine (0.08 ± 0.02 vs. 0.007 ± 0.01 mg/mg, p <0.001, decreased in both patient groups but more so in the high PTH-M group), and for the 24-hour urinary calcium(128 ± 22 vs. 86 ± 11 mg, p < 0.001) which was only reduced (p < 0.001) in normals. Serum osteocalcin, although raised in both groups, did not differ significantly between patient groups (15.1 ± 2.3 ng/ml for hyperparathyroid patients and 14.4 ± 5.2 ng/ml for normals), but was significantly different between patients and controls (6.8 ± 3.1 ng/ml, p < 0.001). Histomorphometrically, trabecular bone volume was elevated in both groups as compared to controls (p < 0.001), and the resorption surface was increased in hyperparathyroid patients (9.7 ± 1.1 vs. 4.7 ±2.8%, p < 0.001), as was the osteoid seam thickness index (31.8 ± 6.2 vs. 18.6 ± 5.6, p < 0.001). According to the Pearson test, only effected in the normoparathyroid group, the only significant and positive correlations were between osteocalcin and 24-hour urine calcium and between osteocalcin and Ca/Cr (both p < 0.001). These results demonstrate the existence of a secondary hyperparathyroidism in 10% of patients with blastic bone metastases due to stage-D prostatic cancer and show that osteocalcin is not an adequate biological bone marker in these patients.

Keywords:
Hyperparathyroidism, Prostate cancer, Osteoblastic metastases, Histomorphometry, Osteocalcin
This content is only available via PDF.
1990
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.